Related Experiment Video
Updated: Aug 4, 2026
09:09
High Throughput, Real-time, Dual-readout Testing of Intracellular Antimicrobial Activity and Eukaryotic Cell Cytotoxicity
Published on: November 16, 2016
Lincomycin-curare interaction
Anesthesia and Analgesia
|January 11, 1975
Summary
Lincomycin (LCN) can cause respiratory issues when combined with d-tubocurarine (DTC). This study in cats found LCN does not worsen neuromuscular blockade from DTC, suggesting careful monitoring is needed for patients on both drugs.
Area of Science:
- Anesthesiology
- Pharmacology
- Respiratory Physiology
Background:
- Lincomycin (LCN) has been associated with respiratory insufficiency.
- d-tubocurarine (DTC) is a neuromuscular blocking agent.
- The potential interaction between LCN and DTC requires investigation.
Purpose of the Study:
- To investigate the interaction between lincomycin and d-tubocurarine in a feline model.
- To determine if lincomycin exacerbates neuromuscular blockade induced by d-tubocurarine.
Main Methods:
- Cats were anesthetized with halothane-nitrous-oxide-oxygen.
- Sciatic nerve stimulation was used to assess neuromuscular function.
- Dose-response curves for DTC were generated in control and LCN-treated groups.
Main Results:
- Lincomycin (10 mg/kg) did not alter the neuromuscular blocking effects of d-tubocurarine.
- No significant difference was observed in the log-dose response curves for DTC between groups.
- Cats receiving LCN during recovery from DTC showed no change in the slope or y-intercept.
Conclusions:
- Lincomycin does not potentiate the neuromuscular blockade of d-tubocurarine in this feline model.
- The findings suggest that the respiratory insufficiency observed clinically may be due to other mechanisms.
- Further research is needed to elucidate the exact cause of LCN-induced respiratory issues.
Related Concept Videos
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
01:27Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
01:11Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics
All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
01:28Depolarizing Blockers: Mechanism of Action
Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because succinylcholine...
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because succinylcholine...
01:19Depolarizing Blockers: Pharmocokinetics
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
01:21Skeletal Muscle Relaxants: Adverse Effects
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Unlike...